相关实验视频

Updated: Sep 13, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

卡姆雷利祖马布,一种抗PD-1单克隆抗体,加上卡博普拉丁和纳布-帕克利塔塞尔作为扩散阶段小细胞肺癌的第一线设置:第二阶段试验和生物标志物分析

Jia Yu¹, Deyu Cai^2,3, Sha Zhao¹

¹Department of Medical Oncology Shanghai Pulmonary Hospital, School of Medicine, Tongji University Shanghai People's Republic of China.

|July 29, 2025

概括

卡姆雷利祖马布加化学疗法作为扩散阶段小细胞肺癌 (ES-SCLC) 的一线治疗方法具有前景,显示52.2%的6个月无进展生存率. 生物标志物分析确定了治疗反应的潜在预测因素.

科学领域:

医学瘤学医学瘤学
免疫治疗是一种免疫疗法.
基因组学就是基因组学.

背景情况:

扩散阶段小细胞肺癌 (ES-SCLC) 的第一线治疗选择有限.
化学免疫疗法组合正在探索,以改善ES-SCLC的结果.

研究的目的:

评估卡姆雷利祖马布与卡博普拉丁和纳布-帕克利塔塞尔结合在ES-SCLC的第一线治疗中的疗效,安全性和预测生物标志物.
识别与治疗反应相关的潜在基因组和转录基因组标记物.

主要方法:

一项涉及60名ES-SCLC患者的临床试验,这些患者接受了卡梅利祖马布加卡博普拉丁和纳布-帕克利塔塞尔.
治疗包括四到六个周期,然后是维护性康雷利祖马布.
在瘤样本上进行了全外体和转录组测序,以确定预测生物标志物.

主要成果:

6个月无进展生存率 (PFS) 为52.2%,符合主要终点.
平均PFS为7.1个月,平均整体存活时间 (OS) 为18.1个月.
目标反应率 (ORR) 为73.3%,疾病控制率 (DCR) 为93.3%.
MUC17变化或高NEUROG1表达与更短的PFS和OS有关.
通过转录组分析确定了两个不同的免疫子集.

结论:

卡姆雷利祖马布与卡博普拉丁和纳布-帕克利塔塞尔结合似乎是ES-SCLC的可行的一线治疗选择.
多原子数据集成可以阐明化学免疫治疗反应的复杂机制.
MUC17和NEUROG1可以作为治疗结果的潜在预测生物标志物.

关键词:

这是ES-SCLCLC.生物标志物生物标志物卡梅里兹马巴姆的摄像头免疫疗法免疫疗法纳布-帕克利塔克塞尔 (NAB-paclitaxel) 是一种药物.

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...